Coversin in Paroxysmal Nocturnal Haemoglobinuria (PNH) in Patients With Resistance to Eculizumab Due to Complement C5 Polymorphisms
Phase of Trial: Phase II
Latest Information Update: 02 Feb 2017
At a glance
- Drugs Coversin (Primary)
- Indications Paroxysmal nocturnal haemoglobinuria
- Focus Therapeutic Use
- Sponsors Akari Therapeutics
- 23 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2018.
- 23 Jan 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2018.
- 19 May 2016 Interim results (n=1) published in Akari Therapeutics media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History